/
Rare Disease
Duchenne Muscular Dystrophy
40
Pipeline Programs↗
53
Active Trials↗
37
Companies Involved↗
Duchenne Muscular Dystrophy is a moderately active landscape with 40 programs across 37 companies. The most active players are Sarepta Therapeutics, NS Pharma, Edgewise Therapeutics, Inc.. 9 programs are in Phase 3.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical16
Phase 14
Phase 211
Phase 39
Approved
No programs
Analysis
Modality Breakdown
86%
Small molecule
24 of 28 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 28 classified programs, each share of the total. Modality classified for 85% of 40 pipeline programs.
Analysis
Trial Status
185
clinical trials
Completed81 · 44%
Terminated32 · 17%
Active, not recruiting23 · 12%
Recruiting19 · 10%
Not yet recruiting8 · 4%
Unknown status8 · 4%
Other14 · 8%
Clinical Trials
Trial Activity
185 trials
Phase-2 Trial of 5mg/kg/Week Prednisolone in Young Boys With DMD
Recruiting·—·Approved·NCT05412394·26 enrolled
Page 1 of 13
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)